SAN DIEGO, May 19, 2015 /PRNewswire/ -- Pharmatek, a contract development and manufacturing organization supporting the pharmaceutical industry, today announced that it has completed installation of a GEA Niro Mobile Minor™ for the GMP manufacture of amorphous spray dried dispersions. The Company is currently completing equipment validation. The spray dryer is complemented by the Company's purchase last year of a Gerteis MINI-PACTOR™.
The Mobile Minor acquisition increases the Company's current spray-drying capabilities. Pharmatek first invested in spray drying in 2011 with the purchase of a Buchi B-290 for small-scale spray dried productions. The Company has seen growing demand in this area and has received specific requests from clients to increase spray dry capacity.
In order to provide greater flexibility, Pharmatek's GMP spray drying capabilities will include aqueous and solvent processing in a closed loop system. Additionally, the spray dryer will be installed in the Company's high containment manufacturing facility, allowing for the manufacture of highly potent and cytotoxic compounds.
"Spray drying has become an essential option for anyone specializing in the development of poorly soluble compounds. Over the past five years, we've developed a tremendous amount of expertise in amorphous dispersion development for poorly soluble compounds," stated Jeffrey Bibbs, CEO and CSO of Pharmatek. "This increased capacity allows Pharmatek to offer spray drying support through Phase 2b clinical studies."
"We continue to invest in our client's needs. And investment in the larger spray dryer is part of the company's ongoing efforts to provide comprehensive solutions for our clients," said Tim Scott, president of Pharmatek. "The Mobile Minor adds to our portfolio of bioavailability enhancement technologies, including micronization, hot-melt complexation, and liquid-filled-capsule development."
Pharmatek is a dosage form development and GMP manufacturing company providing full-service pharmaceutical chemistry product development and manufacturing for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, clinical packaging, labeling and distribution, and cytotoxic and high-potency drug development.
Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the website http://www.pharmatek.com or by calling 858-805-6383.
Elizabeth Hickman, Associate Director, Marketing
Pharmatek Laboratories, Inc.